Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...
November 11, 2024--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today ...
Pharmaceutical Technology on MSN4d
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART HytruloZai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
Zacks.com on MSN11d
Why Argenx (ARGX) Might be Well Poised for a SurgeArgenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
On Tuesday, Wolfe Research upgraded argenx SE (NASDAQ: ARGX) stock from Peerperform to Outperform with a price target of $697.00. The firm anticipates a positive trajectory for the company through ...
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...
(NASDAQ:ARGX – Get Free Report) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” ...
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and ...
On Tuesday, Wolfe Research upgraded argenx SE (NASDAQ: ARGX) stock from Peerperform to Outperform with a price target of $697.00. The firm anticipates a positive trajectory for the company through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback